U.S. License Holder:
Servier Pharma LLC
Date of License:
December-20-2018
Last Update:
Dec-15-2024
FDA-Approved Indications
ASPARLAS (calaspargase pegol-mknl) is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.